<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03112135</url>
  </required_header>
  <id_info>
    <org_study_id>assuit university hospital</org_study_id>
    <nct_id>NCT03112135</nct_id>
  </id_info>
  <brief_title>Effect of Topical and Systemic Tranexemic Acid on Bleeding During Ear Exploration Surgery</brief_title>
  <official_title>Effect of Topical and Systemic Tranexemic Acid on Bleeding and Quality of Surgical Field During Ear Exploration Surgery. A Double Blind Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of tranexamic acid (TXA) on bleeding and improvement of surgical field during ear&#xD;
      exploration surgery is not clear yet. This study will conducted to answer this question.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bleeding during ear surgery is still a challenge for surgeons and anesthesiologists .&#xD;
      Although extensive blood loss is rare during ear surgery, however, establishing a favorite&#xD;
      surgical field is often difficult. The reason is that even slight bleeding may distort the&#xD;
      view of the field and increase the occurrence of complications, including deafness, the&#xD;
      longer duration of surgery, or even inconclusive surgery .&#xD;
&#xD;
      Many techniques have been proposed to improve the field of ear exploration surgery. Bipolar&#xD;
      diathermy, packing, local vasoconstrictors, and induced hypotension are the most commonly&#xD;
      used techniques . Diathermy can lead to local damage and delayed bleeding . Using topical&#xD;
      vasoconstrictions can lead to hemodynamic instability especially in patients with a history&#xD;
      of hypertension or ischemic heart disease. Induction hypotension exposes the patients to more&#xD;
      anesthetic drugs and hence a higher risk of potential side effects. However, neither of these&#xD;
      methods guarantees a desirable surgical field with no bleeding. Therefore, investigators are&#xD;
      working on more effective and safer methods to reduce bleeding and hence to improve the field&#xD;
      of surgery .&#xD;
&#xD;
      Activation of fibrinolysis during and after surgery is a well-known phenomenon. Many&#xD;
      mechanisms associated with coagulation disorders, such as surgical trauma, blood loss and&#xD;
      consumption of coagulation factors and platelets, using crystalloid and colloid given during&#xD;
      and after surgery, hypothermia, acidosis, foreign materials, and etc. In recent studies,&#xD;
      systemic infusion of anti-fibrinolytic drugs have been used to reduce bleeding in various&#xD;
      forms of surgery such as major orthopedic surgery,and adeno-tonsillectomy.&#xD;
&#xD;
      Tranexamic acid (TXA) is a synthetic antifibrinolytic agent that binds to the lysine binding&#xD;
      sites of plasmin and plasminogen. Saturation of the binding sites causes separation of&#xD;
      plasminogen from superficial fibrin and hence prevents fibrinolysis. Any surgical procedure&#xD;
      can cause a considerable tissue damage and hence trigger the release of enzymes, such as&#xD;
      'tissue plasminogen activator' that converts plasminogen to plasmin and activates&#xD;
      fibrinolysis process. TXA can prevent fibrinolysis activity by inhibiting the activity of&#xD;
      this enzyme.&#xD;
&#xD;
      Systemic infusion of TXA associated with several potential side effects such as nausea,&#xD;
      vomiting, diarrhea, allergic dermatitis, dizziness, hypotension, seizures, impaired vision,&#xD;
      achromatopsia (impaired color vision), and particularly thromboembolic events. Several&#xD;
      studies have been conducted on topical TXA in different types of surgery but no systemic&#xD;
      absorption or side effects have been reported.&#xD;
&#xD;
      To date, the effect of TXA on reduction of bleeding in ear surgery is unclear . There is no&#xD;
      consensus on the efficacy of TXA and its effective dose in reducing bleeding. This trial will&#xD;
      aim to assess the effect of topical TXA on bleeding and improvement of surgical field during&#xD;
      ear surgery in patients with chronic ear disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">April 2017</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The quality of the surgical field</measure>
    <time_frame>45 minutes after the start of surgery</time_frame>
    <description>Boezaart grading with 0-5 scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>intraoperative blood loss</measure>
    <time_frame>45 minutes after the start of surgery</time_frame>
    <description>Blood in the suction and the gauze</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Intraoperative Bleeding</condition>
  <arm_group>
    <arm_group_label>Systemic TXA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TXA 10-15 mg i.v over 30 min. followed by infusion in a dose of 1 mg / kg /hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TXA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical TXA 1 gm diluted in 200 ml saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical adrenaline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical adrenaline 1 mg diluted in 200 ml saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr</description>
    <arm_group_label>Systemic TXA</arm_group_label>
    <other_name>kapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Topical TXA 1 gm diluted in 200 ml saline</description>
    <arm_group_label>Topical TXA</arm_group_label>
    <other_name>kapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adrenalin</intervention_name>
    <description>Topical adrenaline 1 mg diluted on 200 ml saline</description>
    <arm_group_label>Topical adrenaline</arm_group_label>
    <other_name>Epinephrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. being candidate for ear exploration surgery.&#xD;
&#xD;
          2. ASA I-II&#xD;
&#xD;
          3. Willing to participate in the study&#xD;
&#xD;
          4. Hb level &gt; 10 mg/dl.&#xD;
&#xD;
          5. normal coagulation profile (INR and PTT )&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal&#xD;
&#xD;
          2. allergy toTXA&#xD;
&#xD;
          3. Bleeding disorder&#xD;
&#xD;
          4. psychiatric illness&#xD;
&#xD;
          5. acute and chronic renal failure&#xD;
&#xD;
          6. using heparin during 48 hr before surgery&#xD;
&#xD;
          7. pregnancy&#xD;
&#xD;
          8. cirrhosis&#xD;
&#xD;
          9. colour blindness&#xD;
&#xD;
         10. cardiac stent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sally Ahmed, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut Univerisity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Ahmed, Dr</last_name>
    <phone>01068668302</phone>
    <phone_ext>088</phone_ext>
    <email>Sallyahmed720@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Egypt</name>
      <address>
        <city>Asyut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sally Ahmed, Dr</last_name>
      <phone>01068668302</phone>
      <phone_ext>088</phone_ext>
      <email>Sallyahmed720@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2017</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Sally Ahmed kamel</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

